Transactivator From the X-gene Region (Tax)
Alfa Cytology provides efficient solutions for targeting tax drug development services through in-depth investigation of the HTLV-1 Tax protein, we explore its critical role in viral gene expression. Using advanced experimental techniques and bioinformatics analysis, we validate Tax as a viable drug target.
Oncogenic Functions of HTLV-1 Tax
Tax plays a pivotal role in controlling the expression of viral genes and enlists host transcription factors like cyclic AMP response element-binding protein along with coactivators, such as CREB binding protein and p300, to the long terminal repeat for stimulating the viral promoter. Studies have demonstrated that HTLV-1 Tax exerts a pro-survival function in T cells affected by the virus through augmenting the levels of antiapoptotic proteins from the Bcl-2 family.
Fig. 1. The immunodominant protein Tax will be presented via MHCI on latently infected cells. (Schnell, A.P. et al., 2021)
Development of Latency Reversing Agents
Our services focus on the development of novel therapeutic strategies aimed at transiently inducing viral gene expression and antigen presentation of Tax. This disruption of equilibrium is advantageous for enhancing the CTL response against HTLV-1.
Development of HDACi
Our HDACi development services are built upon an established pharmacophore model. The overall framework comprises a cap, which binds to the HDAC surface, facilitating ligand-receptor interactions. A hydrophobic linker region connects the cap to a zinc-binding group (ZBG), serving as the functional moiety of the HDACi. We offer development services for various categories of HDACi.
- Cyclopeptide
- Short-Chain Fatty Acids
- Benzamides
- Hydroxamates
Development of P-TEFb-modulating agents
P-TEFb activity is regulated through its interaction with various proteins. We provide development services for Agents that target both high molecular weight (HMW) and low molecular weight (LMW) complexes. The Agents developed by our team can specifically target these complexes to facilitate the release of P-TEFb, promoting its binding with the Tax.
| Services | Description |
|---|---|
| Agents Interfering with the HMW | We offer development services for Agents Interfering with the HMW, along with efficacy assessment and testing in HTLV-1-infected cells. |
| Agents Interfering with the LMW-Complex | Based on the two conserved tandem bromodomain structures of BRD4, a key member of the LMW complex, we offer screening services in compound libraries to identify candidate drugs that interfere with the acetylation of histones and the interaction with BET proteins. |
Development of Immunotherapy
Therapeutic Antibodies Development Services
By combining the advantages of a diversified antibody library with a therapeutic antibody discovery technology suite, we harness the potential of antibodies with broad epitope coverage, diverse antibody formats, valences, and sizes to identify antibodies targeting specific epitopes.
Tax-targeted Vaccine Development Services
We aim to develop a novel therapeutic vaccine targeting HTLV-1 regulatory protein, TAX, to activate Tax-specific CTLs, with the expectation of generating anti-ATL effects without graft-versus-host (GVH) reactions. The discovered Tax-DC vaccination comprises of autologous dendritic cells pulsed with Tax peptides.
As a trusted provider of HTLV-1 drug development services, Alfa Cytology is committed to delivering high-quality scientific support. Our expert team, state-of-the-art facilities, and comprehensive solutions empower your HTLV-1 drug development projects for success. Contact us for more information or to arrange a consultation.
Reference
- Schnell, A.P.; et al. Latency Reversing Agents: Kick and Kill of HTLV-1? International Journal of Molecular Sciences. 2021. 22(11): 5545.